[Treatment of patients with severe glucocorticoid-refractory ulcerative colitis: cyclosporine or infliximab?]

Ned Tijdschr Geneeskd. 2013;157(38):A6130.
[Article in Dutch]

Abstract

Cyclosporine and infliximab are so-called 'rescue-therapies' as last resort for the treatment of patients with severe glucocorticoid-refractory ulcerative colitis. A recent study found that cyclosporine and infliximab are similar in terms of efficacy in the treatment of patients with severe ulcerative colitis. Cyclosporine may be prescribed as a bridge to treatment with thiopurines; infliximab may be prescribed when a patient is intolerant or refractory to thiopurines. Preoperative treatment with cyclosporine or infliximab does not affect the number of postoperative complications.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Colectomy
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / surgery
  • Cyclosporine / therapeutic use*
  • Glucocorticoids / therapeutic use
  • Humans
  • Infliximab
  • Postoperative Complications / epidemiology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Glucocorticoids
  • Cyclosporine
  • Infliximab